CHLOROTHIAZIDE

Trade Name	Biomed suspension
Class	Thiazide diuretic
Mechanism of Action	Inhibits sodium reabsorption in the distal tubules Increases loss of sodium, potassium, magnesium, chloride, bicarbonate and, phosphate Decreases calcium loss
Indications	Chronic lung disease Congestive heart failure
Contraindications	Hyperbilirubinaemia. Anuria. Severe renal or hepatic failure. Hypercalcaemia. Hypersensitivity to sulphonamide derived drugs.
Supplied As	50mg/mL (oral suspension)
Dilution	Not required.
Dosage	10 – 20 mg/kg/dose
Interval	12 hourly
Administration	Oral with feed
Incompatible With	Do not draw up dose into an oral syringe containing any other medications
Interactions	Steroids due to potentiation of potassium loss.
	Risk of Milk-alkali syndrome with high calcium doses. When used with digoxin may increase risk of digoxin toxicity.
Monitoring	Serum electrolytes, glucose, uric acid and renal function.
Stability	As per date on bottle, preservative free. Discard 7 days after opening
Storage	Refrigerate, shake before use.
Adverse Reactions	GI upset, hyperbilirubinaemia, cholestasis, pancreatitis, Electrolye disturbances including hypokalaemia, hypomagnesaemia, hyponatraemia, hypercalcaemia, hyperchloraemic alkalosis, hyperglycaemia, hyperuricaemia Cardiac arrhythmias Hypersensitivity reactions including pneumonitis and pulmonary
	oedema. Photosensitivity.
Metabolism	Poor oral absorption 10 - 20%. Onset 2 hours, peak 4 hours, excreted unchanged in the urine. Half life 5 hours.

Comments	Diuretic effect potentiated when used in combination with spironolactone, frusemide. Displaces bilirubin from albumin. Due to manufacturing difficulties Hydrochlorothiazide may need to be used – dose equivalent is 0.5-1 mg/kg/dose 12 hourly Section 29 – unapproved medicine
References	 Cochrane library: Brion LP; Diuretics acting on the distal renal tubule for preterm infants with CLD: 2000, issue 1. Medicines for children, July 1999, RCPCH, pg 105. Neofax 1999 (12th ed) pg 146. Pediatric dosage handbook 1999-2000 (6th ed) pg 199. www.anmfonline.org www.nzf.org
Updated By	Dr R Martin June 2000. N Austin December 2001 P Schmidt, B Robertshawe December 2004 A Lynn, B Robertshawe Feb 2009 A Lynn, B Robertshawe June 2012 (re-order profile) A Lynn, M Wallenstein, B Robertshawe November 2020 A Lynn, B Robertshawe March 2023. (Change from per day to per dose)